ASCO 2022 Conference Coverage

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Breast
Lung
GI
GU
Skin
GYN
Head & Neck
Leukemia
Lymphoma
Myeloma
MDS and MPN
Sarcoma

Playback speed

July 9, 2022

Feat. H. Rugo

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

S. De Botton

ASCO 2022 Conference Coverage

S. De Botton

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

C. Papayannidis

ASCO 2022 Conference Coverage

C. Papayannidis

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

ASCO 2022 Conference Coverage

C. Gambacorti-Passerini

Login

Login

Join VuMedi

ASCO 2022 Conference Coverage

Lecture Summary - ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) in Late-Stage Mutant-IDH2 R/R AML Treated With Enasidenib or Conventional Care Regimens in the Phase 3 IDHENTIFY Trial

Unmet Needs for Patients With HR+, HER2- Early Breast Cancer at a Hi…

Communicating the Risk of Recurrence for Patients With HR+, HER2- Ea…

Lecture Summary - ASCO 2022 Efficacy & Safety Results From the Phase…

ASCO 2022 Efficacy & Safety Results From the Phase 3 ASCEMBL Study o…

Lecture Summary - ASCO 2022 on Overall Survival by IDH2 Mutant Allel…

ASCO 2022 on Overall Survival by IDH2 Mutant Allele (R140 or R172) i…

ASCO 2022 Updated Results From a Phase II Study of mini-HCVD + Ino +…

ASCO 2022 Treatment-Free Remission in CML Patients Following the Dis…

Lecture Summary - ASCO 2022 Treatment-Free Remission in CML Patients…

Lecture Summary - ASCO 2022 Updates on the Evolution of Asparaginase…

ASCO 2022 Updates on the Evolution of Asparaginase in the Management…

Lecture Summary - ASCO 2022 on Leveraging AML Genomics Across the Th…

ASCO 2022 on a Phase 1b Study of Blinatumomab With the Anti-Programm…

Lecture Summary - ASCO 2022 on a Phase 1b Study of Blinatumomab With…

ASCO 2022 on a Phase II Study of Hyper-CVAD With Sequential Blina +/…

Lecture Summary - ASCO 2022 on a Phase II Study of Hyper-CVAD With S…

ASCO 2022 Bosutinib in Newly Diagnosed CML: Gastrointestinal, Liver,…

Lecture Summary - ASCO 2022 Bosutinib in Newly Diagnosed CML: Gastro…

ASCO 2022 Efficacy and Safety of Bosutinib in Later-Line Patients Wi…